Hydration Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Hydration Pharmaceuticals's earnings have been declining at an average annual rate of -21.6%, while the Personal Products industry saw earnings growing at 8.7% annually. Revenues have been growing at an average rate of 22.9% per year.
Key information
-21.6%
Earnings growth rate
5.0%
EPS growth rate
| Personal Products Industry Growth | -25.2% |
| Revenue growth rate | 22.9% |
| Return on equity | n/a |
| Net Margin | -79.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Hydration Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 10 | -8 | 12 | 0 |
| 31 Mar 24 | 10 | -8 | 12 | 0 |
| 31 Dec 23 | 10 | -8 | 13 | 0 |
| 30 Sep 23 | 10 | -9 | 14 | 0 |
| 30 Jun 23 | 10 | -10 | 15 | 0 |
| 31 Mar 23 | 10 | -10 | 15 | 0 |
| 31 Dec 22 | 9 | -11 | 15 | 0 |
| 30 Sep 22 | 9 | -11 | 14 | 0 |
| 30 Jun 22 | 8 | -11 | 14 | 0 |
| 31 Mar 22 | 7 | -10 | 12 | 0 |
| 31 Dec 21 | 6 | -9 | 10 | 0 |
| 30 Sep 21 | 5 | -6 | 7 | 0 |
| 30 Jun 21 | 4 | -4 | 5 | 0 |
| 31 Mar 21 | 4 | -2 | 5 | 0 |
| 31 Dec 20 | 4 | -1 | 5 | 0 |
| 31 Dec 19 | 3 | -3 | 5 | 0 |
| 31 Dec 18 | 4 | -10 | 9 | 0 |
Quality Earnings: HPC is currently unprofitable.
Growing Profit Margin: HPC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HPC is unprofitable, and losses have increased over the past 5 years at a rate of 21.6% per year.
Accelerating Growth: Unable to compare HPC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HPC is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (10.2%).
Return on Equity
High ROE: HPC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.